Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-11-01, Stock:ABBV, The news for the past five days is as follows:
2021-10-25: NEWS1: Buy This Great High-Yield Dividend Stock?.NEWS2: AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know.NEWS3: Investors in AbbVie (NYSE:ABBV) have made a strong return of 138% over the past five years.NEWS4: What Could These Clinical Results Mean for AbbVie's Shareholders?.
2021-10-26: NEWS1: AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?.NEWS2: The 7 Best Stocks to Buy to Profit From the Rich.NEWS3: Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia.
2021-10-27: NEWS1: AbbVie Stock Is Making A Comeback On Inflammatory Drugs — Is It A Buy Now?.NEWS2: Recovery in Drugs Sales to Aid AbbVie's (ABBV) Q3 Earnings.NEWS3: Healthcare ETFs in Focus as Q3 Earnings Unfold.NEWS4: AbbVie Takes Another Step Toward Its Post-Humira Future.NEWS5: 3 Stocks You Can Still Buy on Sale in a Ridiculously Expensive Market.
2021-10-28: NEWS1: What Investors Should Pay Attention to in AbbVie's Q3 Earnings Report.NEWS2: Should Investors Worry About AbbVie?.NEWS3: AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease.
2021-10-29: NEWS1: U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision).NEWS2: AbbVie Performs Third-Quarter Hat Trick — Here's What You Need To Know.NEWS3: AbbVie (ABBV) Q3 2021 Earnings Call Transcript.NEWS4: AbbVie Stock Rises on Earnings Beat and Guidance Boost.NEWS5: Why AbbVie Shares Are Rising Today.NEWS6: Why Are CareDx Shares Slumping Despite Q3 Earnings Beat?.NEWS7: AbbVie Performs Third-Quarter Hat Trick — Here's What You Need To Know.NEWS8: AbbVie's (ABBV) Q3 Earnings Beat, 2021 EPS Guidance Raised.NEWS9: Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab.NEWS10: Drug maker AbbVie reports 'excellent' third quarter.NEWS11: Abbvie Jumps After Raising Dividend, Annual Profit Forecast.NEWS12: 5 Top Gainers for Friday: U.S. Steel, Lululemon, VeriSign.NEWS13: AbbVie's Major Depressive Disorder Candidate Shows Mixed Result In Late-Stage Trials.NEWS14: AbbVie (ABBV) Tops Q3 Earnings Estimates.NEWS15: AbbVie Stock Nears Breakout After Topping Forecasts As Botox Sales Rocket.NEWS16: UPDATE 2-AbbVie confident of blockbuster drug replacements, lifts profit view third time.NEWS17: AbbVie Stock Gains After Hiking FY21 Earnings Outlook, Annual Dividend.NEWS18: AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder.NEWS19: AbbVie confident of blockbuster drug replacements, lifts profit view third time.NEWS20: AbbVie gets a shot in the arm from newer drug sales, lifts profit view.NEWS21: AbbVie Reports Third-Quarter 2021 Financial Results.NEWS22: AbbVie Stock Rises on Stronger-Than-Expected Q3, Lifted Guidance.NEWS23: Premarket Movers Friday - Amazon, AbbVie, Apple.

Answer: Rise